A new study suggests that a single dose of zaleplon at the start of CPAP titration during split-night polysomnography does not result in superior CPAP adherence or improved symptoms at one month. Published in the May 15 issue of the Journal of Clinical Sleep Medicine, the study involved 134 patients newly diagnosed with obstructive sleep apnea. Complete follow-up data were available for 83 subjects. Results show that both the zaleplon group and the placebo group used CPAP for an average of 6.5 hours per night.
